News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
40,104 Results
Type
Article (2577)
Company Profile (45)
Press Release (37481)
Multimedia
Podcasts (9)
Webinars (2)
Section
Business (14194)
Career Advice (78)
Deals (2108)
Drug Delivery (9)
Drug Development (4144)
Employer Resources (10)
FDA (443)
Job Trends (782)
News (20275)
Policy (1058)
Tag
Academia (144)
Allergies (7)
Alliances (3491)
ALS (6)
Alzheimer's disease (59)
Antibody-drug conjugate (ADC) (27)
Approvals (446)
Artificial intelligence (31)
Autoimmune disease (8)
Automation (2)
Bankruptcy (13)
Best Places to Work (476)
BIOSECURE Act (2)
Biosimilars (16)
Biotechnology (29)
Bladder cancer (8)
Brain cancer (7)
Breast cancer (44)
Cancer (324)
Cardiovascular disease (10)
Career advice (66)
Career pathing (1)
CAR-T (31)
CDC (1)
Cell therapy (81)
Cervical cancer (2)
Clinical research (3437)
Collaboration (199)
Company closure (2)
Compensation (104)
COVID-19 (185)
CRISPR (11)
C-suite (112)
Cystic fibrosis (7)
Data (418)
Denatured (6)
Depression (11)
Diabetes (17)
Diagnostics (488)
Digital health (2)
Diversity (2)
Diversity, equity & inclusion (1)
Drug discovery (36)
Drug pricing (10)
Duchenne muscular dystrophy (40)
Earnings (4501)
Editorial (5)
Employer branding (1)
Employer resources (8)
Events (6403)
Executive appointments (134)
FDA (588)
Friedreich's ataxia (4)
Frontotemporal dementia (1)
Funding (167)
Gene editing (32)
Generative AI (1)
Gene therapy (55)
GLP-1 (63)
Government (158)
Guidances (24)
Healthcare (708)
HIV (1)
Huntington's disease (5)
IgA nephropathy (12)
Immunology and inflammation (34)
Immuno-oncology (14)
Indications (4)
Infectious disease (197)
Inflammatory bowel disease (15)
Inflation Reduction Act (6)
Influenza (7)
Intellectual property (25)
Interviews (7)
IPO (1002)
IRA (7)
Job creations (293)
Job search strategy (62)
JPM (4)
Kidney cancer (6)
Labor market (11)
Layoffs (51)
Leadership (3)
Legal (215)
Liver cancer (6)
Longevity (1)
Lung cancer (28)
Lymphoma (12)
Machine learning (3)
Management (4)
Manufacturing (52)
MASH (14)
Medical device (314)
Medtech (315)
Mergers & acquisitions (1220)
Metabolic disorders (72)
Multiple sclerosis (22)
Neurodegenerative disease (27)
Neuropsychiatric disorders (10)
Neuroscience (164)
NextGen: Class of 2026 (353)
Non-profit (155)
Now hiring (11)
Obesity (32)
Opinion (17)
Ovarian cancer (17)
Pain (24)
Pancreatic cancer (21)
Parkinson's disease (11)
Partnered (4)
Patents (53)
Patient recruitment (25)
Peanut (1)
People (5877)
Pharmaceutical (5)
Pharmacy benefit managers (1)
Phase 1 (1474)
Phase 2 (1702)
Phase 3 (915)
Pipeline (390)
Policy (17)
Postmarket research (30)
Preclinical (641)
Press Release (2)
Prostate cancer (7)
Psychedelics (3)
Radiopharmaceuticals (14)
Rare diseases (62)
Real estate (425)
Recruiting (5)
Regulatory (916)
Reports (7)
Research institute (149)
Resumes & cover letters (9)
Rett syndrome (1)
RNA editing (5)
RSV (1)
Schizophrenia (16)
Series A (46)
Series B (20)
Service/supplier (2)
Sickle cell disease (3)
Special edition (3)
Spinal muscular atrophy (2)
Sponsored (1)
Startups (497)
Stomach cancer (2)
Supply chain (4)
Tariffs (2)
The Weekly (3)
Vaccines (52)
Venture capital (15)
Weight loss (21)
Women's health (10)
Worklife (1)
Date
Last 7 days (39)
Last 30 days (147)
Last 365 days (2411)
2026 (211)
2025 (2438)
2024 (2612)
2023 (2858)
2022 (3750)
2021 (4048)
2020 (3473)
2019 (2064)
2018 (1555)
2017 (1795)
2016 (1625)
2015 (1833)
2014 (1370)
2013 (1190)
2012 (1396)
2011 (1332)
2010 (1181)
Location
Africa (44)
Alabama (3)
Arizona (18)
Asia (1946)
Australia (307)
California (1601)
Canada (241)
China (80)
Colorado (54)
Connecticut (16)
Delaware (5)
Europe (4016)
Florida (64)
Georgia (11)
Hawaii (2)
Idaho (3)
Illinois (21)
India (2)
Indiana (60)
Japan (17)
Kansas (14)
Kentucky (1)
Maryland (48)
Massachusetts (568)
Michigan (14)
Minnesota (22)
Mississippi (1)
Missouri (4)
Nebraska (1)
Nevada (3)
New Hampshire (4)
New Jersey (133)
New York (80)
North Carolina (131)
Northern California (781)
Ohio (44)
Oklahoma (2)
Oregon (6)
Pennsylvania (109)
Puerto Rico (1)
Rhode Island (2)
South America (40)
South Carolina (1)
Southern California (652)
Tennessee (4)
Texas (152)
United States (3202)
Utah (5)
Virginia (11)
Washington D.C. (3)
Washington State (95)
West Virginia (1)
Wisconsin (13)
40,104 Results for "vedanta biosciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Vedanta ‘Significantly’ Reduces Staff, Focuses on Phase III Study of
C. Diff
Drug
Less than six months after cutting 20% of its employees, Vedanta Biosciences has again laid off staff. According to one affected staffer, half of
the Cambridge, Massachusetts–based biotech’s workforce is being cut while most of the rest are furloughed.
January 16, 2026
·
2 min read
·
Angela Gabriel
Layoffs
Vedanta Downsizes by 20% After Phase II Stumble in Ulcerative Colitis
Vedanta is parting ways with 23 employees, or approximately 20% of its headcount, after Phase II data for microbiome therapy VE202 failed to demonstrate significant response rates in patients with ulcerative colitis.
August 14, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
August 14, 2025
·
4 min read
Press Releases
PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
August 14, 2025
·
8 min read
Genetown
Vedanta Biosciences to Present at Upcoming Investor Conferences - April 29, 2024
Vedanta Biosciences today announced that members of its executive team will participate at the following investor conferences.
April 29, 2024
·
1 min read
Press Releases
Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
January 23, 2025
·
5 min read
Genetown
Vedanta Biosciences to Participate at Upcoming Investor Conferences
Vedanta Biosciences today announced that members of its executive team will participate at the following investor conferences.
October 5, 2023
·
1 min read
Genetown
Vedanta Biosciences to Host Investor Meetings at the Leerink Partners 2024 Global Biopharma Conference
Vedanta Biosciences announced that management will host investor meetings at the Leerink Partners 2024 Global Biopharma Conference being held in Miami, FL from Monday, March 11 through Wednesday, March 13, 2024.
March 6, 2024
·
1 min read
Press Releases
PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
January 27, 2025
·
10 min read
Drug Development
Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection
Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, announced that the first patient has been dosed in the global Phase 3 RESTORATiVE303 clinical study.
May 21, 2024
·
5 min read
1 of 4,011
Next
